| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 三生国健是中国首批专注于创新型抗体药物研究并持续积极创新，拥有研、产、销一体化成熟平台，专注于单抗、双抗、多抗及多功能重组蛋白等新技术研究。公司拥有超过18年大规模抗体产业化和质量控制经验，并多维度布局CDMO业务，巩固和增强创新型治疗药物企业的领导地位。目前，公司拥有13个处于不同开发阶段的在研创新药物，其中大部分在研药物为治疗用生物制品1类，部分在研药物为中美双报。 | ||||||||||||||||||||||||
| Main Business | 为自身免疫性疾病、肿瘤等重大疾病治疗领域提供高品质、安全有效的临床解决方案。 | ||||||||||||||||||||||||
| Legal Representative | LOU JING | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 刘彦丽 | ||||||||||||||||||||||||
| Solicitors | 北京市中伦律师事务所 | ||||||||||||||||||||||||
| Auditors | 安永华明会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 021-80297676 | ||||||||||||||||||||||||
| Fax No | 021-80297676 | ||||||||||||||||||||||||
| Website | www.3s-guojian.com | ||||||||||||||||||||||||
| ir@3s-guojian.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 22/07/2020 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.480 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.050 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 7.938 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 13.427B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |